Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: The GERA study

Physiological Genomics

Volumn 39, Issue 1, 2009, Pages 56-60

  Barbalic, Maja ^a   Schwartz, Gary L ^b   Chapman, Arlene B ^c   Turner, Stephen T ^b   Boerwinkle, Eric ^a,d  

^a UNIVERSITY OF TEXAS   (United States)

^b MAYO CLINIC   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antihypertensive treatment; Candidate genes

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; CANDESARTAN; HYDROCHLOROTHIAZIDE; KININOGEN; SODIUM;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL WALL; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CONTROL GROUP; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG RESPONSE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; EUROPEAN AMERICAN; EXPERIMENTAL STUDY; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART; HUMAN; KIDNEY; KIDNEY DISEASE; KININOGEN GENE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; KININOGENS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 70349147456     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00061.2009     Document Type: Article

References (26)

1. Batenburg WW, Tom B, Schuijt MP, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation. Focus on bradykinin, NO and endothelium-derived hyperpolarizing factor(s). Vascul Pharmacol 42: 109-118, 2005.
2. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B: 289-300, 1995.
3. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44: 1-80, 1992.
4. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci 23: 374-380, 2002.
5. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens 21: 61-66, 2008.
6. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, Brooks LD, Cardon LR, Daly M, Donnelly P, Fraumeni JF Jr, Freimer NB, Gerhard DS, Gunter C, Guttmacher AE, Guyer MS, Harris EL, Hoh J, Hoover R, Kong CA, Merikangas KR, Morton CC, Palmer LJ, Phimister EG, Rice JP, Roberts J, Rotimi C, Tucker MA, Vogan KJ, Wacholder S, Wijsman EM, Winn DM, Collins FS. Replicating genotype-phenotype associations. Nature 447: 655-660, 2007.
7. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 61: 1047-1055, 2002. (Pubitemid 34175474)
8. Cheung PP, Kunapuli SP, Scott CF, Wachtfogel YT, Colman RW. Genetic basis of total kininogen deficiency in Williams' trait. J Biol Chem 268: 23361-23365, 1993. (Pubitemid 23328058)
9. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and postacute myocardial infarction pathophysiology. Am J Cardiol 97: 4F-12F, 2006. (Pubitemid 43673930)
10. Emanueli C, Angioni GR, Anania V, Spissu A, Madeddu P. Blood pressure responses to acute or chronic captopril in mice with disruption of bradykinin B2-receptor gene. J Hypertens 15: 1701-1706, 1997. (Pubitemid 28029667)
11. Erdmann J, Hegemann N, Weidemann A, Kallisch H, Hummel M, Hetzer R, Fleck E, Regitz-Zagrosek V. Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: identification of a functional mutation in the promoter and a new coding variant (T21M). Am J Med Genet 80: 521-525, 1998. (Pubitemid 29002023)
12. Hanke CJ, Bauer-Dantoin AC. Teaching aldosterone regulation and basic scientific principles using a classic paper by Dr. James O. Davis and colleagues. Adv Physiol Educ 30: 141-144, 2006.
13. Kurland L, Liljedahl U, Lind L. Hypertension and SNP genotyping in antihypertensive treatment. Cardiovasc Toxicol 5: 133-142, 2005. (Pubitemid 41058627)
14. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 95: 221-227, 2005. (Pubitemid 43093236)
15. Lim PO, Jung RT, MacDonald TM. Is aldosterone the missing link in refractory hypertension? Aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens 16: 153-158, 2002.
16. Lundwall A, Clauss A, Olsson AY. Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors. Biol Chem 387: 243-249, 2006.
17. Lunetta KL. Genetic association studies. Circulation 118: 96-101, 2008.
18. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, Dessi-Fulgheri P, Sarzani R, Anania V. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96: 3570-3578, 1997. (Pubitemid 27513435)
19. Margolius HS. Theodore Cooper Memorial Lecture. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 26: 221-229, 1995.
20. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74: 765-769, 2004.
21. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 89: 4221-4226, 2004. (Pubitemid 39244414)
22. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 16: 104-107, 2005.
23. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 47: 312-318, 2006.
24. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 37: 1811-1819, 1991.
25. Sealey JE, Laragh JH. Searching out low renin patients: limitations of some commonly used methods. Am J Med 55: 303-314, 1973.
26. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the reninangiotensin- aldosterone system. Nat Rev Drug Discov 1: 621-636, 2002.